--- title: "Hong Kong Pharma Digital Faces Delay in Annual Filing" type: "News" locale: "en" url: "https://longbridge.com/en/news/294561922.md" description: "Hong Kong Pharma Digital Technology Holdings Ltd. filed Form 12b-25 to delay its annual Form 20-F for the year ended March 31, 2026, citing unanticipated delays in financial statement preparation. Preliminary data indicates a sharp deterioration in performance, with net loss widening to $1.09 million from $0.03 million and revenues falling 39% to $7.56 million due to weaker supply chain services. The company expects to file within fifteen days of the original deadline under SEC Rule 12b-25 relief." datetime: "2026-07-31T22:18:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294561922.md) - [en](https://longbridge.com/en/news/294561922.md) - [zh-HK](https://longbridge.com/zh-HK/news/294561922.md) generator: "portal-rs" --- # Hong Kong Pharma Digital Faces Delay in Annual Filing Hong Kong Pharma Digital Technology Holdings Ltd. ( (HKPD) ) has released a notification of late filing. ### Claim 55% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Hong Kong Pharma Digital Technology Holdings Ltd., through Cellyan Biotechnology Co., Ltd., has filed a Form 12b-25 related to its delayed Form 20-F (Yearly Report) for the financial year ended March 31, 2026. The company disclosed that unanticipated delays in completing its financial statements and related disclosures prevented timely filing of the annual Form 20-F (Yearly Report). Management said the delay could not be resolved without unreasonable effort or expense, indicating internal timing and preparation issues rather than a change of auditor or regulatory investigation. There is no mention of problems with prior filings, and all other required periodic reports over the past 12 months have been submitted. The company expects to file the Form 20-F (Yearly Report) within fifteen calendar days after the original due date, in line with the relief allowed under SEC Rule 12b-25. Investors should watch that window closely, as the filing will contain the final audited numbers and fuller commentary on the year’s performance. Preliminary figures point to a sharp deterioration in financial performance, with a net loss of about $1.09 million for the year ended March 31, 2026 versus a net loss of roughly $0.03 million in the prior year. Revenues fell about 39% to $7.56 million, and gross profit dropped around 43% to $1.39 million, driven mainly by weaker supply chain services and procurement and distribution revenue. The company also reported that net loss attributable to shareholders jumped to approximately $1.11 million, compared with only $0.01 million a year earlier, underscoring margin pressure and a tougher operating environment. These numbers are still under review by internal accounting staff and independent auditors, and may change materially once the Form 20-F (Yearly Report) is officially filed, making them subject to the usual forward-looking statement risks. Management included standard forward-looking language, warning that expectations around future strategy, demand, competition and regulation involve uncertainties that could cause actual results to differ. The notification signals that the company is working to finalize its statements and remain compliant with SEC reporting rules. The filing is signed on behalf of Cellyan Biotechnology Co., Ltd. by Chief Executive Officer Chenyu Liang on July 31, 2026, confirming executive responsibility for the delayed submission and for the company’s plan to complete the annual Form 20-F (Yearly Report) promptly. **More about Hong Kong Pharma Digital Technology Holdings Ltd.** Hong Kong Pharma Digital Technology Holdings Ltd. is a Hong Kong-based company operating through Cellyan Biotechnology Co., Ltd., focusing on supply chain services, procurement and distribution in the pharmaceutical and biotechnology space. The business appears exposed to shifts in demand for its services, with revenues tied closely to the performance of its logistics and sourcing operations. **Average Trading Volume:** 840,592 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** $4.35M ### Related Stocks - [HKPD.US](https://longbridge.com/en/quote/HKPD.US.md) ## Related News & Research - [Madrigal Pharma director John C. Reed files initial beneficial ownership statement](https://longbridge.com/en/news/296270622.md) - [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md) - [Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2](https://longbridge.com/en/news/296129489.md) - [REG - Diageo PLC - Publication of 2026 Annual Report and Form 20-F](https://longbridge.com/en/news/296223610.md) - [Gary Stetz Discloses Investment at Hepion Pharmaceuticals with 5.7% Stake](https://longbridge.com/en/news/296534320.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**